Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure
CardiacWire
JULY 28, 2024
These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways… JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notable given that all other TAVR systems only address aortic stenosis.
59 
Let's personalize your content